AGP Executive Report
Last update: 3 hours agoCardiovascular Research: Novartis-backed pelacarsen lowered Lp(a) substantially but failed to reduce heart attacks, strokes or deaths in a major trial, raising questions about the strategy. Treatment Advances: The FDA granted accelerated approval to J&J’s Rybrevant Faspro for head and neck cancer and approved a once-monthly injectable olanzapine for schizophrenia; a Huntington disease gene therapy also won priority review. Gene therapies are bringing relief to some people with sickle cell disease. Public Health: The U.S. measles count topped 5,100 this year, with nearly all cases in people whose vaccination status was unvaccinated or unknown. An NIH study linked higher levels of two PFAS chemicals to increased rates of aggressive breast cancer, but not breast cancer overall. Industry: Indian drugmakers are investing in domestic API and peptide manufacturing to reduce import reliance and build higher-value production. CVS plans to separate its retail pharmacies from its specialty operations.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
